<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690309</url>
  </required_header>
  <id_info>
    <org_study_id>Polish Society Of Diabetology</org_study_id>
    <nct_id>NCT04690309</nct_id>
  </id_info>
  <brief_title>Human Versus Analogue Insulin in Patients After Pancreatectomy.</brief_title>
  <official_title>Human Versus Analogue Insulin in Patients After Pancreatectomy - Open, Prospective, Randomized, Intervention Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Society of Diabetology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polish Society of Diabetology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatectomy is a common treatment modality for both benign and malignant pathologies. One&#xD;
      of the most common complications after pancreatectomy is pancreatogenous diabetes mellitus.&#xD;
      Yet, insulin remains treatment of choice in patients after pancreatectomy, however there is&#xD;
      little evidence on the choice of insulin preparation in patients with diabetes after&#xD;
      pancreatectomy. In particular, it is unclear whether human or analogue insulin should be&#xD;
      preferred in this group of patients.The aim of the study was to compare human vs analog&#xD;
      insulin therapy in patients with diabetes prior to or diabetes developing after&#xD;
      pancreatectomy performed due to pancreatic tumor. The study was designed as an open,&#xD;
      prospective, randomized, intervention study.All patients provided written comprehensive&#xD;
      informed consent. After surgery all patients who underwent total pancreatectomy were treated&#xD;
      with insulin, while the patients who had partial pancreatectomy performed were treated with&#xD;
      basal insulin when fasting plasma glucose exceeded 140 mg/dl and with prandial insulin when&#xD;
      2-hour postprandial plasma glucose exceeded 180 mg/dl.The patients who required insulin&#xD;
      treatment after surgery were randomized with the use of random numbers generator&#xD;
      (www.randomizer.org) into two groups: Group 1 - treated with insulin analogues (lispro,&#xD;
      glargine), Group 2 - treated with human insulin preparations (regular and NPH insulin).The&#xD;
      clinical and metabolic assessment was carried out 3 and 6 months after surgery. The study was&#xD;
      approved by Local Ethics Committee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.</measure>
    <time_frame>Change in concentration of glycated hemoglobin from baseline to concentration of glycated hemoglobin 6 months after surgery in patients treated with human insulin and insulin analogues</time_frame>
    <description>Metabolic control in patients treated with human insulin and insulin analogues will be assessed using glycated hemoglobin concentration (mmol/mol)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.</measure>
    <time_frame>Change in concentration of glycated hemoglobin from baseline to concentration of glycated hemoglobin 3 months after surgery in patients treated with human insulin and insulin analogues</time_frame>
    <description>Metabolic control in patients treated with human insulin and insulin analogues will be assessed using glycated hemoglobin concentration (mmol/mol)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatogenous Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients treated with human insulin preparations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper and with Neutral Protamine Hagedorn insulin (isofane insulin) administered subcutaneously before sleep.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with insulin analogues</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper and with glargine administered subcutaneously before sleep.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with human insulin preparations or treatment with insulin analogues</intervention_name>
    <description>The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting &lt; 100 mg/dl (5.5 mmol/L) and postprandial &lt; 140 mg/dl (7.8mmol/L)</description>
    <arm_group_label>Patients treated with human insulin preparations</arm_group_label>
    <arm_group_label>Patients treated with insulin analogues</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        •Patients with pancreatic tumor confirmed in imaging studies and qualified for surgical&#xD;
        treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        •Active psychiatric disease not amenable to treatment and hindering cooperation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jolanta B Jurczyńska, PhD</last_name>
    <phone>+ 48 533 699 069</phone>
    <email>jolanta.jurczynska@wum.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Warsaw Medical University</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneta Wojda</last_name>
      <phone>+ 48 22 599 25 83</phone>
      <email>kdw.csk@uckwum.pl</email>
    </contact>
    <investigator>
      <last_name>Jolanta B Jurczyńska</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wojciech Korcz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustaw Lech</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sally Hammoud</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Waldemar Pawłowski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Słodkowski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leszek Czupryniak</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>January 2, 2021</last_update_submitted>
  <last_update_submitted_qc>January 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human insulin</keyword>
  <keyword>insulin analogues</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

